<DOC>
	<DOCNO>NCT01634191</DOCNO>
	<brief_summary>The purpose study evaluate effect age sex pharmacokinetics , safety single oral dose 30 mg apremilast healthy subject .</brief_summary>
	<brief_title>Pharmacokinetics Apremilast ( CC-10004 ) Healthy Elderly Subjects</brief_title>
	<detailed_description>This open-label , parallel group study eligible elderly subject ( age 65-85 year inclusive ) young subject ( age 18-55 year inclusive ) match elderly subject sex BMI ( Â± 10 % ) receive single dose 30 mg apremilast fasting condition . The subject check study center Day -1 , dose Day 1 , discharge study center Day 3 schedule pharmacokinetic blood draw safety evaluation .</detailed_description>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria elderly group 1 . Healthy male female subject ethnic origin age 65 85 inclusive body mass index ( BMI ) 18 35 . 2 . Females must surgically sterilize least 6 month prior screen postmenopausal ( confirm lab test ) . 3 . Males must agree use latex polyurethane condom engage sex study least 28 day dose . 4 . Elderly subject stable , chronic medical condition may eligible condition wellcontrolled medication interfere study procedure pharmacokinetic interpretation Inclusion Criteria young group : 1 . Healthy male female ethnic origin age 18 55 inclusive BMI 18 35 . 2 . Males must agree use latex polyurethane condom engage sex study least 28 day dose . 3 . Females able become pregnant negative pregnancy test screen baseline , must agree use one following : highly effective form contraception ( ex . Nonoral hormonal , intrauterine device ) OR oral hormonal contraceptive plus one additional form barrier contraception OR two form barrier contraception These must effective time screen . For young female able become pregnant , condition elderly female apply . 1 . Any condition , include presence laboratory abnormality , psychiatric illness , would prevent subject signing Informed Consent form , place subject unacceptable risk participate study , confound ability interpret data study . 2 . Presence surgical medical condition possibly affect drug absorption , distribution , metabolism , excretion , plan elective medical procedure conduct trial . 3 . Exposure investigational drug ( new chemical entity ) within 30 day prior first dose administration 5 halflives investigational drug , know ( whichever longer ) . 4 . Subjects know serum hepatitis , know carrier hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus antibody . 5 . Subjects use prescription systemic topical medication within 30 day dose , unless use treat stable , chronic medical condition . This include medication inhibitor inducer Pglycoprotein transporter CYP3A4/5 use within 14 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Apremilast</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>safety</keyword>
	<keyword>Pharmacokinetics safety healthy volunteer subject</keyword>
</DOC>